Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease | Zendy

Christopher P. Can | Zendy; Irfan Khan | Zendy; Alexa C. Klimchak | Zendy; Matthew R. Reynolds | Zendy; Robert J. Sanchez | Zendy; William J. Sasiela | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease

Author(s) -

Christopher P. Can,

Irfan Khan,

Alexa C. Klimchak,

Matthew R. Reynolds,

Robert J. Sanchez,

William J. Sasiela

Publication year - 2017

Publication title -

jama cardiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.108

H-Index - 63

eISSN - 2380-6591

pISSN - 2380-6583

DOI - 10.1001/jamacardio.2017.2289

Subject(s) - ezetimibe , medicine , alirocumab , pcsk9 , evolocumab , atorvastatin , statin , cohort , population , kexin , cholesterol , lipoprotein , ldl receptor , environmental health , apolipoprotein a1

In patients with atherosclerotic cardiovascular disease (ASCVD), guidelines recommend optimizing statin treatment, and consensus pathways suggest use of ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in patients with persistently elevated low-density lipoprotein cholesterol (LDL-C) levels despite use of statins. Recent trials have provided evidence of benefit in reduction of cardiovascular events with these agents.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research